MetaCap

Armata Pharmaceuticals (ARMP) vs Invivyd (IVVD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Armata Pharmaceuticals (ARMP) has outperformed Invivyd (IVVD) over the past year, losing 56.9% versus a loss of 83.5%. Over five years, ARMP leads with a -42.0% price change compared with -98.4% for IVVD. Invivyd is the larger company by market cap ($122.0 million vs $112.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARMP-56.90%IVVD-83.49%
+120%+14%-93%
Nov 21, 20251 yearNov 20, 2026
ARMP-22.70%IVVD-97.94%
+246%+66%-115%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARMP versus IVVD key metrics
MetricARMPIVVD
Share price$3.03$0.4127
Market cap$112.69M$122.01M
1-day change+1.68%-7.45%
YTD return-51.75%-83.29%
1-year return-56.90%-83.49%
5-year return-41.95%-98.36%
EPS (TTM)$-4.17$-0.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$53.43M
Revenue growth (YoY)—+110.47%
Net income (latest FY)$-173.80M$-52.49M
Operating margin—-103.99%
Net margin—-98.25%
52-week high$14.98$3.01
52-week low$2.40$0.4127
Distance from 52-week high-79.77%-86.29%
Analyst consensusnonestrong_buy
Avg. price target upside+477.56%+2323.07%
Average volume182.52K5.20M
Shares outstanding37.19M295.63M
Employees61122
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARMP has outperformed IVVD by 26.6 percentage points over the past year.

About Armata Pharmaceuticals

ARMP stock →

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees

About Invivyd

IVVD stock →

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees

ARMP vs IVVD FAQ

Which is bigger, Armata Pharmaceuticals or Invivyd?

Invivyd (IVVD) is larger, with a market capitalization of $122.01M compared with $112.69M for Armata Pharmaceuticals (ARMP).

Which stock has performed better over the past year, ARMP or IVVD?

ARMP returned -56.90% over the past 12 months, compared with -83.49% for IVVD (price return, excluding dividends). Past performance does not predict future results.

Are Armata Pharmaceuticals and Invivyd in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons